Clinical Trial

Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)

Completed Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Protocol Amendment History 5 changes
critical Trial completed 2026-08-14
critical Phase changed: Phase 1 -> Phase 2 2026-08-14
notable Enrollment reduced: 200 -> 96 participants 2026-08-14
notable Primary completion moved earlier: 2026-05-31 -> 2026-04-04 2026-08-14
minor Completion moved earlier: 2026-05-31 -> 2026-04-04 2026-08-14
Trial Details
NCT Number NCT06203977
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: Hamilton Academic Health Sciences Organization, St. Joseph's Health Care London
Conditions Chronic Kidney Diseases, Renal Failure
Enrollment 96 participants
Start Date 2024-11-15
Primary Completion 2026-04-04 (estimated)
Study Completion 2026-04-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-13